These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29774766)

  • 61. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
    Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
    Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
    Nouhaud FX; Rebibo JD; Blanchard F; Sabourin JC; Di Fiore F; Pfister C
    Prog Urol; 2014 Jul; 24(9):563-71. PubMed ID: 24975791
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
    Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
    Gu W; Wang B; Gan H; Zhu Y; Wang H; Shi G; Zhou L; Zhang H; Ye D
    Future Oncol; 2016 Aug; 12(15):1783-93. PubMed ID: 27174049
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Patterns of care and outcomes for second-line targeted therapy in metastatic renal cell carcinomas: A registry based analysis.
    Zanwar S; Joshi A; Noronha V; Patil VM; Sable N; Popat P; Menon S; Kothari R; Bhargava P; Kapoor A; Prabhash K
    Indian J Cancer; 2016; 53(4):579-582. PubMed ID: 28485356
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
    Ornstein MC; Rini BI
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
    Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases.
    Kalra S; Atkinson BJ; Matrana MR; Matin SF; Wood CG; Karam JA; Tamboli P; Sircar K; Rao P; Corn PG; Tannir NM; Jonasch E
    BJU Int; 2016 May; 117(5):761-5. PubMed ID: 26032863
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
    Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
    J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
    Marschner N
    Onkologie; 2010; 33 Suppl 1():12-4. PubMed ID: 20164671
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
    Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
    Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma.
    Chedgy EC; Black PC
    Urology; 2016 Mar; 89():8-9. PubMed ID: 26723186
    [No Abstract]   [Full Text] [Related]  

  • 77. Site-specific Response to Nivolumab in Renal Cell Carcinoma.
    Negishi T; Furubayashi N; Nakagawa T; Nishiyama N; Kitamura H; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Okajima E; Nakamura M
    Anticancer Res; 2021 Mar; 41(3):1539-1545. PubMed ID: 33788747
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma.
    Takagi T; Yoshida K; Kobayashi H; Kondo T; Iizuka J; Okumi M; Ishida H; Fukuda H; Ishihara H; Tanabe K
    Jpn J Clin Oncol; 2018 Sep; 48(9):860-863. PubMed ID: 30113653
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice.
    Joseph RW; Chatta G; Vaishampayan U
    Urol Oncol; 2017 Apr; 35(4):142-148. PubMed ID: 28259541
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.
    Akbaraly T; Saguintaah M; Topart D; Sirvent N
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):251-252. PubMed ID: 29420369
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.